Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    51,118.67
    +1,556.66 (+3.14%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Merck KGaA to continue testing cancer vaccine

Reuters - UK Focus

FRANKFURT, Sept 25 (Reuters) - Germany's Merck KGaA (Other OTC: MKGAY - news) said it would start a new study testing its experimental lung cancer vaccine Stimuvax, which fell through in a previous late-stage trial.

Merck said on Tuesday it would test the drug, which it licensed from U.S. biotech firm Oncothyreon (NasdaqGS: ONTY - news) , on patients with locally advanced Stage III non-small cell lung cancer (NSCLC), which cannot be surgically removed.

Stimuvax, also known as Tecemotide, failed to improve survival in a pivotal study in December, dealing a blow to the company and the high-risk field of using vaccines to fight tumours.

Merck said on Tuesday that data from an analysis of a predefined patient subgroup in this trial, however, showed some promise. (Reporting by Ludwig Burger)